On Jun. 14, 2016, the FDA approved changes to vaccine administrationﾠschedule for Trumenba vaccine produced by Wyeth Pharmaceuticals, a subsidiary of Pfizer. The immunization is to prevent invasive disease caused by Neisseria meningitidis serogroup B in individuals 10 years through 25 years of age.